BridgeMD
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction - NORshock
EU CTIS ID: 2024-510892-40-00
What this study is testing
The primary objective of this study is to test whether a treatment strategy with reduced use of noradrenaline in patients with cardiogenic shock is superior to standard care in terms of combined all-cause mortality and renal failure at 30 days.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Acute myocardial infarction, STEMI or NSTEMI
- Early revascularization by PCI
- Cardiogenic shock, characterized by: I. a. Systolic blood pressure (SBP) < 90 mmHg for > 30 minutes, OR b. Use of drugs to maintain SBP > 90 mmHg at presentation before randomization. II. Clinical signs of impaired organ perfusion with at least one of the following criteria: a. Altered mental status b. Cold, clammy skin and extremities c. Oliguria with urine output < 30ml/hour d. Serum lactate > 2.0 mmol/L III. Clinical signs of pulmonary congestion
You likely can't join if
- Resuscitation > 30 minutes
- Mechanical cause of cardiogenic shock (e.g. papillary muscle rupture, ventricular septal rupture)
- Onset of shock > 12 hours
- Imminent need for mechanical circulatory support (i.e. ECPR patients)
- Women < 45 years
The study team makes the final eligibility decision.
Where it's taking place
- Serbia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Serbia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.